Quarterly ResultMay 6, 2026, 04:10 PM

KORU Medical Q1 Revenue +22.1% to $11.8M; Net Loss Narrows to $0.8M

AI Summary

KORU Medical Systems reported a 22.1% increase in net revenues to $11.8 million for the first quarter of 2026, with net loss narrowing by 30.8% to $0.8 million. The company saw strong growth across all segments, particularly in pharma services and clinical trials. Additionally, CEO Linda Tharby announced her retirement, transitioning to an advisory role, and the company amended its loan agreement to extend maturities and lower interest rates.

Key Highlights

Net revenues increased 22.1% to $11.8 million for Q1 2026, up from $9.6 million in Q1 2025.
Net loss narrowed by 30.8% to $(0.8) million in Q1 2026, compared to $(1.2) million in Q1 2025.
Basic and diluted net loss per share improved to $(0.02) in Q1 2026 from $(0.03) in Q1 2025.
Domestic core revenues grew 11.7% to $7.7 million, driven by higher consumable volumes.
International core revenues increased 35.2% to $3.3 million, due to higher pump and consumable volumes.
Pharma services and clinical trials revenues surged 166.0% to $0.7 million.
CEO Linda Tharby announced retirement, transitioning to a non-executive advisory employee by June 30, 2026.
Loan agreement amended, extending revolver maturity to March 30, 2028, and term loan maturity to December 1, 2029.

View SEC Filing

KRMD

Medical/Dental Instruments

KORU Medical Systems, Inc.

Price Impact